No edit summary |
No edit summary |
||
| Line 26: | Line 26: | ||
}} |
}} |
||
| − | '''Pentylenetetrazol''' (PTZ) is the [[International Nonproprietary Name]] of Metrazol (aka Cardiazol in Europe) and also known as '''pentetrazol''' or '''pentamethylenetetrazol'''. It is a drug used as a circulatory and respiratory stimulant. Larger doses cause [[convulsions]], thus it was commonly used in [[shock therapy]] during the 40s and 50s, as first used by the Hungarian-American neurologist and psychiatrist [[Ladislas J. Meduna]] in 1934. |
+ | '''Pentylenetetrazol''' (PTZ) is the [[International Nonproprietary Name]] of Metrazol (aka Cardiazol in Europe) and also known as '''pentetrazol''' or '''pentamethylenetetrazol'''. It is a drug used as a circulatory and respiratory stimulant. Larger doses cause [[convulsions]], thus it was commonly used in [[shock therapy]] during the 40s and 50s, as first used by the Hungarian-American neurologist and psychiatrist [[Ladislas J. Meduna]] in 1934. Early in his work Meduna replaced camphor with [[pentylenetetrazol]] (Metrazol), an intravenous agent that induced seizures immediately compared with the long delay of 15 to 45 minutes after intramuscular camphor. |
| + | He first published his results in 1935 and then his major text in 1937. ''Die Konvulsionstherapie der Schizophrenie'' describes the results in 110 patients. Of these patients about half recovered. The results were much better for patients who were ill less than a year compared to those who had been ill for many years. |
||
| ⚫ | It |
||
| + | His results were quickly reproduced in many other centers around the world and this form of therapy became widely used and recognized as the first effective treatment for schizophrenia. |
||
| + | |||
| ⚫ | It later proved largely ineffective, and side-effects such as [[seizure]]s are difficult to avoid. Its approval by FDA was revoked in 1982.<ref name="sciam">{{cite news | author = JR Minkel | title = Drug May Counteract Down Syndrome | url = http://www.sciam.com/article.cfm?chanID=sa003&articleID=F9E196DB-E7F2-99DF-385C9F38537F58D6 | publisher = Scientific American | date = February 25, 2007 | accessdate = 2007-03-20}}</ref> but by then its use had been replaced by electrical stimulation, as in [[ECT]] |
||
| + | |||
==Mechanism== |
==Mechanism== |
||
It is considered a [[GABA antagonist]].<ref>[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=mesh&list_uids=68010433&dopt=Full Entry for Pentylenetetrazole] in the [[MeSH]] database</ref> |
It is considered a [[GABA antagonist]].<ref>[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=mesh&list_uids=68010433&dopt=Full Entry for Pentylenetetrazole] in the [[MeSH]] database</ref> |
||
Latest revision as of 11:21, 17 February 2010
Assessment |
Biopsychology |
Comparative |
Cognitive |
Developmental |
Language |
Individual differences |
Personality |
Philosophy |
Social |
Methods |
Statistics |
Clinical |
Educational |
Industrial |
Professional items |
World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
|
Pentylenetetrazol chemical structure | |
| 6,7,8,9-tetrahydro-5H-Tetrazolo(1,5-a)azepine IUPAC name | |
| CAS number 54-95-5 |
ATC code R07AB03 |
| PubChem 5917 |
DrugBank [1] |
| Chemical formula | {{{chemical_formula}}} |
| Molecular weight | 138.171 |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Pregnancy category | |
| Legal status | |
| Routes of administration | |
Pentylenetetrazol (PTZ) is the International Nonproprietary Name of Metrazol (aka Cardiazol in Europe) and also known as pentetrazol or pentamethylenetetrazol. It is a drug used as a circulatory and respiratory stimulant. Larger doses cause convulsions, thus it was commonly used in shock therapy during the 40s and 50s, as first used by the Hungarian-American neurologist and psychiatrist Ladislas J. Meduna in 1934. Early in his work Meduna replaced camphor with pentylenetetrazol (Metrazol), an intravenous agent that induced seizures immediately compared with the long delay of 15 to 45 minutes after intramuscular camphor.
He first published his results in 1935 and then his major text in 1937. Die Konvulsionstherapie der Schizophrenie describes the results in 110 patients. Of these patients about half recovered. The results were much better for patients who were ill less than a year compared to those who had been ill for many years.
His results were quickly reproduced in many other centers around the world and this form of therapy became widely used and recognized as the first effective treatment for schizophrenia.
It later proved largely ineffective, and side-effects such as seizures are difficult to avoid. Its approval by FDA was revoked in 1982.[1] but by then its use had been replaced by electrical stimulation, as in ECT
Mechanism
It is considered a GABA antagonist.[2]
The mechanism of the epileptogenic action of PTZ at the cellular neuronal level is still unclear.
Electrophysiological studies have shown it acts at cell membrane level decreasing the recovery time between action potentials by increasing potassium permeability of the axon.
Other studies have implicated an increase in membrane currents of several other ions, such as sodium and calcium, leading to an overall increase in excitability of the neuron membrane.
Uses
Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility. PTZ is also a prototypical anxiogenic drug and, has been extensively utilized in animal models of anxiety. PTZ produces a reliable discriminative stimulus which is largely mediated by the GABAA receptor. Several classes of compounds can modulate the PTZ discriminative stimulus including 5-HT1A, 5-HT3, NMDA, glycine, and L-type calcium channel ligands.[3]
Recently, it has been shown that pentetrazol at non-epileptic doses, along with two other compounds (Picrotoxin and bilobalide) can restore the cognitive function (learning and memory) of a mouse model of Down syndrome by inhibiting GABAA receptor without inducing seizures.[4] These results caused renewed interest in pentetrazol as a potential drug candidate for Down syndrome, although clinical trials are probably still a couple of years away.[1].
The finding of pentetrazol's effectiveness in treating Down Syndrome has lead to it being explored as a means of correcting other learning deficiencies. Specifically, hamsters denied their natural circadian rhythm (though not denied sleep) had their memory restored to near-normal levels when treated with pentetrazol[5].
Alternatives
In 1939, Metrazol (also known as Cardiazol) was replaced by electroconvulsive therapy as the preferred method for inducing seizures in England's mental hospitals.
See also
References
- ↑ 1.0 1.1 includeonly>JR Minkel. "Drug May Counteract Down Syndrome", Scientific American, February 25, 2007. Retrieved on 2007-03-20.
- ↑ Entry for Pentylenetetrazole in the MeSH database
- ↑ Jung M, Lal H, Gatch M (2002). The discriminative stimulus effects of pentylenetetrazol as a model of anxiety: recent developments. Neurosci Biobehav Rev 26 (4): 429–39.
- ↑ Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka R, Garner C (2007). Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci.
- ↑ Ruby et al.; Hippocampal-dependent learning requires a functional circadian system; Proceedings of the National Academy of Sciences of the United States of America, 2008, vol. 105, no. 40,15593-15598
- REDIRECT Template:Other respiratory system products
| This page uses Creative Commons Licensed content from Wikipedia (view authors). |